These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37581276)

  • 1. Identification of Promising Sulfonamide Chalcones as Inhibitors of SARS-CoV-2 3CL
    Pojtanadithee P; Hengphasatporn K; Suroengrit A; Boonyasuppayakorn S; Wilasluck P; Deetanya P; Wangkanont K; Sukanadi IP; Chavasiri W; Wolschann P; Langer T; Shigeta Y; Maitarad P; Sanachai K; Rungrotmongkol T
    J Chem Inf Model; 2023 Aug; 63(16):5244-5258. PubMed ID: 37581276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library.
    Lee JY; Kuo CJ; Shin JS; Jung E; Liang PH; Jung YS
    Bioorg Med Chem Lett; 2021 Jun; 42():128067. PubMed ID: 33957246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Natural Bisbenzylisoquinoline Analogs from the Library of Thai Traditional Plants as SARS-CoV-2 3CL
    Khamto N; Utama K; Tateing S; Sangthong P; Rithchumpon P; Cheechana N; Saiai A; Semakul N; Punyodom W; Meepowpan P
    J Chem Inf Model; 2023 Apr; 63(7):2104-2121. PubMed ID: 36647612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro inhibition and molecular docking of a new ciprofloxacin-chalcone against SARS-CoV-2 main protease.
    Alaaeldin R; Mustafa M; Abuo-Rahma GEA; Fathy M
    Fundam Clin Pharmacol; 2022 Feb; 36(1):160-170. PubMed ID: 34268806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
    Roy R; Sk MF; Jonniya NA; Poddar S; Kar P
    J Biomol Struct Dyn; 2022 Sep; 40(14):6556-6568. PubMed ID: 33682642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL
    Ma L; Xie Y; Zhu M; Yi D; Zhao J; Guo S; Zhang Y; Wang J; Li Q; Wang Y; Cen S
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
    Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
    Pathak N; Chen YT; Hsu YC; Hsu NY; Kuo CJ; Tsai HP; Kang JJ; Huang CH; Chang SY; Chang YH; Liang PH; Yang JM
    ACS Nano; 2021 Jan; 15(1):857-872. PubMed ID: 33373194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidation of the inhibitory activity of plant-derived SARS-CoV inhibitors and their potential as SARS-CoV-2 inhibitors.
    Bello M; Hasan MK
    J Biomol Struct Dyn; 2022; 40(20):9992-10004. PubMed ID: 34121618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum.
    Gyebi GA; Elfiky AA; Ogunyemi OM; Ibrahim IM; Adegunloye AP; Adebayo JO; Olaiya CO; Ocheje JO; Fabusiwa MM
    Comput Biol Med; 2021 Sep; 136():104671. PubMed ID: 34332348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
    Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
    Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
    Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
    Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.
    Meyer-Almes FJ
    Comput Biol Chem; 2020 Oct; 88():107351. PubMed ID: 32769050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CL
    Wang F; Liu D; Gao D; Yuan J; Zhao J; Yuan S; Cen Y; Lin GQ; Zhao J; Tian P
    Int J Biol Macromol; 2024 Apr; 264(Pt 1):130377. PubMed ID: 38395279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL
    Du R; Cooper L; Chen Z; Lee H; Rong L; Cui Q
    Antiviral Res; 2021 Jun; 190():105075. PubMed ID: 33872675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying the natural compound Catechin from tropical mangrove plants as a potential lead candidate against 3CL
    Jha RK; Khan RJ; Parthiban A; Singh E; Jain M; Amera GM; Singh RP; Ramachandran P; Ramachandran R; Sachithanandam V; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022; 40(24):13392-13411. PubMed ID: 34644249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.
    Hoffman RL; Kania RS; Brothers MA; Davies JF; Ferre RA; Gajiwala KS; He M; Hogan RJ; Kozminski K; Li LY; Lockner JW; Lou J; Marra MT; Mitchell LJ; Murray BW; Nieman JA; Noell S; Planken SP; Rowe T; Ryan K; Smith GJ; Solowiej JE; Steppan CM; Taggart B
    J Med Chem; 2020 Nov; 63(21):12725-12747. PubMed ID: 33054210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
    Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
    Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
    Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
    Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.